| __timestamp | Novartis AG | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9086000000 | 94231000 |
| Thursday, January 1, 2015 | 8935000000 | 146394000 |
| Friday, January 1, 2016 | 9039000000 | 188272000 |
| Sunday, January 1, 2017 | 8972000000 | 166707000 |
| Monday, January 1, 2018 | 9074000000 | 401843000 |
| Tuesday, January 1, 2019 | 9402000000 | 560909000 |
| Wednesday, January 1, 2020 | 8980000000 | 722343000 |
| Friday, January 1, 2021 | 9540000000 | 771182000 |
| Saturday, January 1, 2022 | 9996000000 | 877090000 |
| Sunday, January 1, 2023 | 11371000000 | 877387000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of innovation and future growth. Over the past decade, Novartis AG and Sarepta Therapeutics, Inc. have shown contrasting approaches to R&D investment.
From 2014 to 2023, Novartis AG consistently invested heavily in R&D, with expenditures peaking at approximately $11.4 billion in 2023. This represents a steady increase of about 25% from their 2014 spending. In contrast, Sarepta Therapeutics, Inc., while significantly smaller, has shown a remarkable growth trajectory. Their R&D spending surged from around $94 million in 2014 to nearly $878 million in 2023, marking an impressive increase of over 830%.
This data highlights the strategic priorities of these companies: Novartis, with its vast resources, maintains a robust R&D budget, while Sarepta's rapid growth underscores its commitment to innovation in niche markets.
Novartis AG or Sarepta Therapeutics, Inc.: Who Leads in Yearly Revenue?
R&D Insights: How Novartis AG and Blueprint Medicines Corporation Allocate Funds
Research and Development Expenses Breakdown: Novartis AG vs Halozyme Therapeutics, Inc.
Research and Development Expenses Breakdown: Novartis AG vs Pharming Group N.V.
Research and Development Expenses Breakdown: Novartis AG vs Ultragenyx Pharmaceutical Inc.
Neurocrine Biosciences, Inc. vs Sarepta Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Sarepta Therapeutics, Inc. vs Alpine Immune Sciences, Inc.
Analyzing R&D Budgets: Sarepta Therapeutics, Inc. vs Viking Therapeutics, Inc.
Research and Development Expenses Breakdown: Sarepta Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.
Research and Development: Comparing Key Metrics for Sarepta Therapeutics, Inc. and HUTCHMED (China) Limited
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and Celldex Therapeutics, Inc.
Research and Development Expenses Breakdown: Sarepta Therapeutics, Inc. vs Evotec SE